In a meta-analysis conducted by Noh et al., no significant metastatic risk was observed with DPP-4 inhibitors in various primary cancers, including breast cancer, when compared to no antidiabetic therapy among diabetic cancer patients [77]. Here, DPP4 is linked to cancer.